Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma

Abstract

The combination of PDM in patients with pleural mesothelioma is feasible and moderately active. However, the observed level of activity is similar to that obtained with other two-drug regimens.